Advanced search
Publication Cover
Scandinavian Journal of Rheumatology Volume 50, 2021 - Issue 6
Submit an article Journal homepage
125
Views
1
CrossRef citations to date
0
Altmetric
Letters

Too young to fail: a case report on the effectiveness of tocilizumab for paediatric systemic sclerosis-associated interstitial lung disease

V Maniscalco1 Rheumatology Unit, Meyer Children’s University Hospital, Pediatric Residency, University of Florence, Florence, ItalyCorrespondence[email protected]
,
E Marrani1 Rheumatology Unit, Meyer Children’s University Hospital, Pediatric Residency, University of Florence, Florence, Italy
,
E Rossi2 Department of Imaging, Meyer Children’s University Hospital, Florence, Italy
,
I Maccora1 Rheumatology Unit, Meyer Children’s University Hospital, Pediatric Residency, University of Florence, Florence, Italy
,
MV Mastrolia1 Rheumatology Unit, Meyer Children’s University Hospital, Pediatric Residency, University of Florence, Florence, Italy
&
G Simonini2 Department of Imaging, Meyer Children’s University Hospital, Florence, Italy;3 Rheumatology Unit, Meyer Children’s University Hospital, Florence, Italy;4 NEUROFARBA Department, University of Florence, Florence, Italy
Pages 491-492 | Accepted 21 Jan 2021, Published online: 17 Mar 2021

References

  • Rabinovich CE. Challenges in the diagnosis and treatment of juvenile systemic sclerosis. Nat Rev Rheumatol 2011;7:676–80.
  • Zulian F, Martini G. Childhood systemic sclerosis. Curr Opin Rheumatol 2007;19:592–7.
  • Garty BZ, Athreya BH, Wilmott R, Scarpa N, Doughty R, Douglas SD. Pulmonary functions in children with progressive systemic sclerosis. Pediatrics 1991;88:1161–7.
  • Elhai M, Meunier M, Matucci-Cerinic M, Maurer B, Riemekasten G, Leturcq T, et al. Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis 2013;72:1217–20.
  • Shima Y, Kuwahara Y, Murota H, Kitaba S, Kawai M, Hirano T, et al. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology (Oxford) 2010;49:2408–12.
  • Khanna D, Denton CP, Lin CJF, van Laar JM, Frech TM, Anderson ME, et al. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). Ann Rheum Dis 2018;77:212–20.
  • Narváez J, LLuch J, Alegre SJJ, Molina-Molina M, Nolla JM, Castellví I. Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series. Ann Rheum Dis 2019;78:e123.
  • Khanna D, Jahreis A, Lin CJF. Response to: ‘Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series’ by Narváez. Ann Rheum Dis 2019;78:e124.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.